| dc.contributor.author |
Papakonstantinou, E |
en |
| dc.contributor.author |
Lambadiari, V |
en |
| dc.contributor.author |
Dimitriadis, G |
en |
| dc.contributor.author |
Zampelas, A |
en |
| dc.date.accessioned |
2014-06-06T06:52:41Z |
|
| dc.date.available |
2014-06-06T06:52:41Z |
|
| dc.date.issued |
2013 |
en |
| dc.identifier.issn |
18756212 |
en |
| dc.identifier.uri |
http://dx.doi.org/10.2174/15701611113116660176 |
en |
| dc.identifier.uri |
http://62.217.125.90/xmlui/handle/123456789/6122 |
|
| dc.subject |
Blood pressure |
en |
| dc.subject |
Cardiovascular disease |
en |
| dc.subject |
Coronary heart disease |
en |
| dc.subject |
Diabetes mellitus |
en |
| dc.subject |
Lipids |
en |
| dc.subject |
Metabolic syndrome |
en |
| dc.subject.other |
advanced glycation end product |
en |
| dc.subject.other |
glucose |
en |
| dc.subject.other |
high density lipoprotein cholesterol |
en |
| dc.subject.other |
polyol |
en |
| dc.subject.other |
protein kinase C |
en |
| dc.subject.other |
triacylglycerol |
en |
| dc.subject.other |
body fat distribution |
en |
| dc.subject.other |
cardiovascular disease |
en |
| dc.subject.other |
disease control |
en |
| dc.subject.other |
dyslipidemia |
en |
| dc.subject.other |
glucose tolerance |
en |
| dc.subject.other |
human |
en |
| dc.subject.other |
hypertension |
en |
| dc.subject.other |
insulin resistance |
en |
| dc.subject.other |
kidney function |
en |
| dc.subject.other |
lifestyle modification |
en |
| dc.subject.other |
metabolic activation |
en |
| dc.subject.other |
metabolic syndrome X |
en |
| dc.subject.other |
mortality |
en |
| dc.subject.other |
obesity |
en |
| dc.subject.other |
oxidative stress |
en |
| dc.subject.other |
review |
en |
| dc.subject.other |
risk factor |
en |
| dc.title |
Metabolic syndrome and cardiometabolic risk factors |
en |
| heal.type |
other |
en |
| heal.identifier.primary |
10.2174/15701611113116660176 |
en |
| heal.publicationDate |
2013 |
en |
| heal.abstract |
The metabolic syndrome (MetS) is a cluster of metabolic conditions associated to abdominal obesity, such as elevated blood pressure, impaired glucose tolerance, insulin resistance, elevated triglycerides, and low high-density lipo-protein cholesterol concentrations. Each of the associated conditions has an independent effect, but clustering together they become synergistic, making the risk of developing cardiovascular disease (CVD) greater. There is a big debate as to whether the MetS alone or its associated health conditions are more important for CVD incidence and mortality or whether prevention and/or treatment of the MetS will reduce CVD incidence and mortality. This article reviews the evidence that demonstrates that individuals with the MetS are at increased risk for CVD incidence and mortality and discusses these debated issues. © 2013 Bentham Science Publishers. |
en |
| heal.publisher |
Bentham Science Publishers B.V. |
en |
| heal.journalName |
Current Vascular Pharmacology |
en |
| dc.identifier.issue |
6 |
en |
| dc.identifier.volume |
11 |
en |
| dc.identifier.doi |
10.2174/15701611113116660176 |
en |
| dc.identifier.spage |
858 |
en |
| dc.identifier.epage |
879 |
en |